INY-03-041

INY-03-041 is a potent, highly selective and PROTAC-based pan-AKT degrader consisting of the ATP-competitive AKT inhibitor Ipatasertib (HY-15186) conjugated to Lenalidomide (HY-A0003, Cereblon ligand) . INY-03-041 inhibits AKT1, AKT2 and AKT3 with IC50s of 2.0, 6.8 and 3.5 nM, respectively[1].

Product Specifications

CAS Number

[2503017-97-6]

UNSPSC

12352005

Target

Akt; PROTACs

Type

Reference compound

Related Pathways

PI3K/Akt/mTOR; PROTAC

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/iny-03-041.html

Purity

99.74

Solubility

DMSO : ≥ 100 mg/mL

Smiles

O=C(C(N(CC1=C2C=CC=C1CCCCCCCCCCNC[C@H](C3=CC=C(Cl)C=C3)C(N4CCN(C5=C([C@H](C)C[C@H]6O)C6=NC=N5)CC4)=O)C2=O)CC7)NC7=O

Molecular Formula

C44H56ClN7O5

Molecular Weight

798.41

References & Citations

[1]You I, et al. Discovery of an AKT Degrader with Prolonged Inhibition of Downstream Signaling. Cell Chem Biol. 2020 Jan 16;27 (1) :66-73.e7.|[2]Maira SM, et al. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol Cancer Ther. 2012 Feb;11 (2) :317-28.